glp-1 obesity drug news october 9 2025 Harvard Business Review | A PwC analysis shows that medications like Ozempic and Zepbound may be catalyzing a behavioral and economic shift on par with major Patients seeking cheaper weight-loss drugs

However, they work through different receptor systems and have different drug profiles

It only means that the FDA wants more definitive long-term data

An excellent perspective and thought-provoking points from Julie Wichlin, our support group co-ordinator in the USA, whose experience undoubtedly will resonate with many whatever your location

Reactivity of the human thioltransferase (glutaredoxin) C7S, C25S, C78S, C82S mutant and NMR solution structure of its glutathionyl mixed disulfide intermediate reflect catalytic specificity

& Mojsov, S

Excitotoxic potential of the cyanotoxin -methyl-amino-l-alanine (BMAA) in primary human neurons